Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Rev Med Suisse ; 20(859): 238-240, 2024 01 31.
Artículo en Francés | MEDLINE | ID: mdl-38299953


Urology continues its development in minimally invasive surgery, and the year 2023 is marked by important innovations in the different approaches such as endoscopy, laparoscopy, and open surgery. The following innovations are instruments or medical devices which are still being evaluated. What they have in common is a questioning of our current practices, on the technical side but also for some of them on the ecological vision of our profession with the eternal debate of single use or reusable. Even if the evaluation of new devices is primarily medical and medico-economic, it is actually no longer possible to ignore the ecological aspect and the impact on the environment of the various new products. New technologies also make it possible to think about smart connected prostheses and precision intraoperative imaging that can ultimately guide the surgeon's hand.

L'urologie est une spécialité en constante évolution. L'année 2023 a été marquée par le développement de nouveautés en chirurgie minimalement invasive, tant en endoscopie qu'en laparoscopie ou chirurgie ouverte, principalement dans les domaines de la robotique, des technologies connectées, ainsi que dans les instruments médicaux réutilisables. Dans le domaine de l'imagerie, le TEP/CT peropératoire pourrait dans l'avenir guider le geste chirurgical afin d'améliorer les résultats oncologiques. Ces nouvelles technologies permettent le développement de nouveaux instruments ou dispositifs médicaux, dont l'évaluation doit se faire aujourd'hui tant sur le plan médical que socio-économique ou écologique.

Laparoscopía , Especialidades Quirúrgicas , Urología , Humanos , Mano
Nat Rev Urol ; 2024 Jan 31.
Artículo en Inglés | MEDLINE | ID: mdl-38297079


Identification of clinically positive pelvic lymph node metastases (cN+) in patients with muscle-invasive bladder cancer is currently challenging, as the diagnostic accuracy of available imaging modalities is limited. Conventional CT is still considered the gold-standard approach to diagnose lymph node metastases in these patients. The development of innovative diagnostic methods including radiomics, artificial intelligence-based models and molecular biomarkers might offer new perspectives for the diagnosis of cN+ disease. With regard to the treatment of these patients, multimodal strategies are likely to provide the best oncological outcomes, especially using induction chemotherapy followed by radical cystectomy and pelvic lymph node dissection in responders to chemotherapy. Additionally, the use of adjuvant nivolumab has been shown to decrease the risk of recurrence in patients who still harbour ypT2-T4a and/or ypN+ disease after surgery. Alternatively, the use of avelumab maintenance therapy can be offered to patients with unresectable cN+ tumours who have at least stable disease after induction chemotherapy alone. Lastly, patients with cN+ tumours who are not responding to induction chemotherapy are potential candidates for receiving second-line treatment with pembrolizumab.

World J Urol ; 42(1): 43, 2024 Jan 20.
Artículo en Inglés | MEDLINE | ID: mdl-38244150


INTRODUCTION AND METHODS: Prostate biopsy (PB) is an essential step in the diagnosis and active surveillance of prostate cancer (PCa). Transperineal PB (TP-PB) is now the recommended approach and is mostly conducted under local anesthesia. However, this procedure can potentially cause anxiety for patients, given the oncological context and the fear of peri-procedural pain and complications. The objective of this narrative review is to summarize the currently available tools for the management of peri-interventional anxiety during TP-PB, with a particular emphasis on the potential role of virtual reality (VR) in this setting. RESULTS: In TP-PB, preoperative anxiety can lead to increased pain perception, longer procedure time, and decreased patient satisfaction. Pharmacological and non-pharmacological approaches have been explored to reduce anxiety, such as premedication, deep sedation, education, relaxation techniques, hypnosis, and music therapy, albeit with mixed results. VR has recently emerged in the technological armamentarium for managing pain and anxiety, and the efficiency of this technology has been evaluated in various medical fields, including pediatrics, gastroenterology, urology, gynecology, and psychiatry. CONCLUSION: Despite the paucity of available data, VR appears to be a safe and effective technique in reducing anxiety in many procedures, even in frail patients. No studies have evaluated the role of VR in TP-PB. Future research should thus explore the optimal way to implement VR technology and any potential benefits for TP-PB patients.

Ansiedad , Biopsia , Próstata , Humanos , Masculino , Anestesia Local , Ansiedad/etiología , Ansiedad/prevención & control , Biopsia/efectos adversos , Biopsia/psicología , Dolor , Próstata/patología
Rev Med Suisse ; 19(852): 2234-2238, 2023 Nov 29.
Artículo en Francés | MEDLINE | ID: mdl-38019538


The detrimental consequences of tobacco use in urology are often underestimated, despite its strong association with urological pathologies, including malignancies, sexual dysfunction, and urinary tract symptoms. Tobacco's components damage DNA, increasing the risk of bladder and urinary tract cancers, as well as renal cancer. In males, it's also correlated with prostate and penile cancers. Functionally, it leads to sexual dysfunctions, reducing erectile capacity and fertility in males. In females, it's linked to elevated urinary incontinence. In both genders, urinary tract symptoms worsen. Smoking cessation is consistently beneficial and should be encouraged by healthcare practitioners.

Les méfaits du tabagisme en urologie sont peu connus, pourtant il provoque diverses pathologies, incluant des cancers urologiques et des troubles sexuels et mictionnels. Les composants du tabac endommagent l'ADN, favorisant la survenue de cancers de la vessie et des voies urinaires, dont il est le principal facteur de risque, ainsi que du rein. Chez l'homme, le tabac accroît également le risque de cancer de la prostate et du pénis. Sur le plan fonctionnel, il induit des troubles sexuels, réduisant l'érection et la fertilité chez l'homme. Chez la femme, l'exposition au tabac est associée à une prévalence augmentée d'incontinence urinaire. Chez les deux sexes, les symptômes mictionnels sont aggravés. Une désintoxication tabagique est toujours bénéfique à court et long termes et doit être encouragée par les praticiens à chaque consultation médicale.

Neoplasias Renales , Cese del Hábito de Fumar , Femenino , Humanos , Masculino , Fumar/efectos adversos , Fumar/epidemiología , Fumar Tabaco , Uso de Tabaco
Rev Med Suisse ; 19(852): 2239-2242, 2023 Nov 29.
Artículo en Francés | MEDLINE | ID: mdl-38019539


Immersive technologies (IT) are undergoing significant expansion in medicine. Among them, virtual augmented or mixed reality offers an interactive or immersive virtual environments to its users, opening a wide array of applications in modern medicine. IT seem particularly interesting in urology, offering a real-time overlay of diagnostic information onto the surgical field and helping visualizing complex anatomical structures, potentially enhancing intraoperative decision-making. Training through realistic simulations with IT represent an excellent and secure tool for trainees and urologists. Finally, patient's comfort during procedures under local anesthesia could be optimized with the use of IT. Further studies are awaited to validate their effectiveness and evaluate their costs to permit their integration into routine medical practice.

Les technologies immersives (TI) connaissent une expansion significative dans le domaine médical. Parmi elles, la réalité virtuelle, augmentée ou mixte offre un environnement virtuel interactif ou immersif à ses utilisateurs, avec une vaste palette d'applications dans la médecine moderne. En urologie, elles sont particulièrement intéressantes, notamment dans la superposition d'informations diagnostiques en temps réel sur le champ opératoire ou la visualisation de structures anatomiques complexes, ce qui peut améliorer la prise de décision peropératoire. La formation à l'aide de simulations réalistes représente un excellent outil pour l'urologue. Enfin, le confort du patient lors des gestes techniques sous anesthésie locale peut être optimisé à l'aide des TI. Des études ultérieures sont nécessaires pour valider leur efficacité et évaluer leur coût avant une intégration dans la pratique médicale courante.

Medicina , Urología , Humanos , Tecnología
World J Urol ; 41(11): 3169-3174, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37755521


PURPOSE: Patients who undergo robot-assisted laparoscopic radical prostatectomy (RARP) may present concurrent or secondary inguinal hernia (IH). Surgical repair of IH simultaneously with RARP has been reported. We aimed to assess the long-term efficacy of concurrent prosthetic IH repair with RARP. METHODS: Data for consecutive patients undergoing concurrent IH repair with RARP for localized prostate cancer at our institution between 2006 and 2017 were retrospectively analysed. Patients were matched based on age, BMI, and year of surgery, with patients undergoing RARP alone. IH repair was performed with a polyester mesh. Efficacy of IH repair was the primary outcome. Patient characteristics, perioperative data, recurrence and treatment were recorded. RESULTS: A total of 136 men were included, 50% treated by RARP and concurrent IH, 50% by RARP alone. Mean age was 65 years (SD 6) and mean BMI 26.8 (SD 2.5). IH was diagnosed preoperatively in 42 patients (62%) or intraoperatively in 26 patients (38%). A total 18 patients (26%) had bilateral hernias and 50 patients had unilateral hernias (right 31%, left 43%). There was no significant difference between the two groups regarding perioperative data. The herniorrhaphy added 34 min to the operative time (p < 0.001). After a mean follow-up of 106 months [SD 38], 9 patients (13%) presented recurrence of IH, with a mean time to recurrence of 43 months [SD 35]. Age was significantly associated with IH recurrence (p = 0.0007). CONCLUSION: Concomitant IH repair and RARP appear to be a safe procedure with good long-term safety and efficacy, without significantly increasing morbidity.

Hernia Inguinal , Laparoscopía , Neoplasias de la Próstata , Procedimientos Quirúrgicos Robotizados , Robótica , Masculino , Humanos , Anciano , Hernia Inguinal/complicaciones , Hernia Inguinal/cirugía , Hernia Inguinal/diagnóstico , Estudios Retrospectivos , Herniorrafia/métodos , Procedimientos Quirúrgicos Robotizados/métodos , Prostatectomía/métodos , Neoplasias de la Próstata/complicaciones , Neoplasias de la Próstata/cirugía , Laparoscopía/métodos
Minerva Urol Nephrol ; 75(5): 591-599, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37728495


BACKGROUND: The existence and prognosis of T1LG (T1 low-grade) bladder cancer is controversial. Also, because of data paucity, it remains unclear what is the clinical history of bacillus Calmette-Guérin (BCG) treated T1LG tumors and if it differs from other NMIBC (non-muscle-invasive bladder cancer) representatives. The aim of this study was to analyse recurrence-free survival (RFS) and progression-free survival (PFS) in patients with T1LG bladder cancers treated with BCG immunotherapy. METHODS: A multi-institutional and retrospective study of 2510 patients with Ta/T1 NMIBC with or without carcinoma in situ (CIS) treated with BCG (205 T1LG patients) was performed. Kaplan-Meier estimates and log-rank test for RFS and PFS to compare the survival between TaLG, TaHG, T1LG, and T1HG NMIBC were used. Also, T1LG tumors were categorized into EAU2021 risk groups and PFS analysis was performed, and Cox multivariate model for both RFS and PFS were constructed. RESULTS: The median follow-up was 52 months. For the T1LG cohort, the estimated RFS and PFS rates at 5-year were 59.3% and 89.2%, respectively. While there were no differences in RFS between NMIBC subpopulations, a slightly better PFS was found in T1LG NMIBC compared to T1HG (5-year PFS; T1LG vs. T1HG: 82% vs. 89%; P<0.001). A heterogeneous classification of patients with T1LG NMIBC was observed when EAU 2021 prognostic model was applied, finding a statistically significant worse PFS in patients classified as high-risk T1LG (5-year PFS; 81.8%) compared to those in intermediate (5-year PFS; 93,4%), and low-risk T1LG tumors (5-year PFS; 98,1%). CONCLUSIONS: The RFS of T1LG was comparable to other NMIBC subpopulations. The PFS of T1LG tumors was significantly better than of T1HG NMIBC. The EAU2021 scoring model heterogeneously categorized the risk of progression in T1LG tumors and the high-risk T1LG had the worst PFS.

Carcinoma de Células Transicionales , Mycobacterium bovis , Neoplasias de la Vejiga Urinaria , Humanos , Vacuna BCG/uso terapéutico , Inmunoterapia , Pronóstico , Estudios Retrospectivos , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico
World J Urol ; 41(11): 3205-3230, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36905443


PURPOSE: To summarize evidence regarding the use of neoadjuvant (NAC) and adjuvant chemotherapy (AC) among patients treated with radical nephroureterectomy (RNU). METHODS: A comprehensive literature search of PubMed (MEDLINE), EMBASE and the Cochrane library was performed to identify any original or review article on the role of perioperative chemotherapy for UTUC patients treated with RNU. RESULTS: With regards to NAC, retrospective studies consistently suggested that it may be associated with better pathological downstaging (pDS) ranging from 10.8 to 80% and complete response (pCR) ranging from 4.3 to 15%, while decreasing the risk of recurrence and death as compared to RNU alone. Even higher pDS ranging from 58 to 75% and pCR ranging from 14 to 38% were observed in single-arm phase II trials. With regards to AC, retrospective studies provided conflicting results although the largest report from the National Cancer Database suggested an overall survival benefit in pT3-T4 and/or pN + patients. In addition, a phase III randomized controlled trial showed that the use of AC was associated with a disease-free survival benefit (HR = 0.45; 95% CI = [0.30-0.68]; p = 0.0001) in pT2-T4 and/or pN + patients with acceptable toxicity profile. This benefit was consistent in all subgroups analyzed. CONCLUSIONS: Perioperative chemotherapy improves oncological outcomes associated with RNU. Given the impact of RNU on renal function, the rational is stronger for the use of NAC which impacts final pathology and potentially prolongs survival. However, the level of evidence is stronger for the use of AC that has been proven to decrease the risk of recurrence after RNU with a potential survival benefit.

Carcinoma de Células Transicionales , Neoplasias Ureterales , Neoplasias de la Vejiga Urinaria , Humanos , Nefroureterectomía/métodos , Carcinoma de Células Transicionales/tratamiento farmacológico , Carcinoma de Células Transicionales/cirugía , Carcinoma de Células Transicionales/patología , Neoplasias de la Vejiga Urinaria/cirugía , Estudios Retrospectivos , Quimioterapia Adyuvante/métodos , Neoplasias Ureterales/tratamiento farmacológico , Neoplasias Ureterales/cirugía , Neoplasias Ureterales/patología , Ensayos Clínicos Controlados Aleatorios como Asunto , Ensayos Clínicos Fase III como Asunto
Eur Urol Oncol ; 6(3): 251-262, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36906510


CONTEXT: Bladder-sparing strategies (BSSs) have been proposed for the treatment of muscle-invasive bladder cancer (MIBC) patients achieving clinical complete response (cCR) to initial systemic treatment to avoid toxicity related to radical cystectomy. OBJECTIVE: To systematically review the current literature evaluating oncological outcomes of BSSs in patients achieving cCR to initial systemic treatment for localized MIBC. EVIDENCE ACQUISITION: A computerized bibliographic search of the Medline, Embase, and Cochrane databases was performed for all studies reporting oncological outcomes of MIBC patients undergoing either surveillance or radiation therapy after achieving cCR to initial systemic treatment. Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we identified 23 noncomparative prospective or retrospective studies published between 1990 and 2021. The mean bladder and metastatic recurrence rates (range) as well as the mean bladder preservation rate (BPR; range) were calculated, and overall survival (OS) was extracted from included reports. EVIDENCE SYNTHESIS: Overall, 16 and seven studies evaluated surveillance (n = 610) and radiation therapy (n = 175) in MIBC patients achieving cCR to initial systemic treatment, respectively. With regard to surveillance, the median follow-up ranged from 10 to 120 mo, with a mean bladder recurrence rate of 43% (0-71%), including 65% of non-muscle-invasive bladder cancer (NMIBC) and 35% of MIBC recurrences. The mean BPR was 73% (49-100%). The mean metastatic recurrence rate was 9% (0-27%), while 5-yr OS rates ranged from 64% to 89%. With regard to radiation therapy, the median follow-up ranged from 12 to 60 mo, with a mean bladder recurrence rate of 15% (0-29%), including 24% of NMIBC, 43% of MIBC, and 33% of unspecified recurrences. The mean BPR was 74% (71-100%). The mean metastatic recurrence rate was 17% (0-22%), while the 4-yr OS rate was 79%. CONCLUSIONS: Our systematic review showed that only low-level evidence supports the effectiveness of BSSs in selected patients achieving cCR to initial systemic treatment for localized MIBC. These preliminary findings highlight the need for further prospective comparative research to demonstrate its efficacy. PATIENT SUMMARY: We reviewed studies evaluating bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer. Based on low-level evidence, we observed that selected patients could benefit from surveillance or radiation therapy in this setting, but prospective comparative research is requested to confirm their efficacy.

Neoplasias de la Vejiga Urinaria , Vejiga Urinaria , Humanos , Vejiga Urinaria/patología , Estudios Retrospectivos , Neoplasias de la Vejiga Urinaria/radioterapia , Neoplasias de la Vejiga Urinaria/patología , Cistectomía , Recurrencia
Nat Rev Urol ; 20(5): 279-293, 2023 05.
Artículo en Inglés | MEDLINE | ID: mdl-36653671


Muscle-invasive bladder cancer (MIBC) is an aggressive disease for which the gold-standard treatment is radical cystectomy (RC) in combination with cisplatin-based neoadjuvant chemotherapy. Bladder-sparing strategies such as trimodal therapy (TMT) have also emerged to improve health-related quality of life (HRQoL) of patients. However, an improved understanding of the effect of all these treatment modalities on HRQoL is essential to provide personalized patient care. Different combinations of generic, cancer-specific and bladder cancer-specific questionnaires can be used as instruments for HRQoL evaluation in patients with MIBC before and after curative treatments, which can largely affect multiple domains of HRQoL including general health as well as physical, functional, social and emotional well-being. However, diagnosis of MIBC per se is also likely to affect HRQoL, and the perspective of cure after RC or TMT could induce a return to baseline HRQoL values for most of these domains. A considerable amount of data on HRQoL after RC is available, but conflicting results have been reported regarding the effect of urinary diversion (ileal conduit or orthotopic neobladder) and surgical approach (open or robotic surgery) on patient quality of life. Data on HRQoL after TMT are scarce, and additional comparative studies including patients receiving RC (especially using ileal orthotopic neobladder) are needed.

Neoplasias de la Vejiga Urinaria , Derivación Urinaria , Humanos , Calidad de Vida/psicología , Neoplasias de la Vejiga Urinaria/cirugía , Cistectomía/métodos , Músculos
Rev Med Suisse ; 18(806): 2274-2277, 2022 Nov 30.
Artículo en Francés | MEDLINE | ID: mdl-36448947


Radiation-induced cystitis (RIHC) is a late complication of pelvic radiation therapy defined by irritative lower urinary tract symptoms with recurrent and sometimes refractory hematuria. Conservative or endoscopic treatments are the first lines, but cystectomy in required in refractory cases. Hyperbaric oxygen therapy (HOT) has recently emerged in the management charts for recurrent and refractory hematuria. Thanks to its neoangiogenic and stem-cell stimulation properties, HOT achieves a complete resolution of hematuria in almost two third of patients and appears to be a good therapeutic alternative for this fragile population. However, its geographical availability is currently limited in Switzerland and its implementation can sometimes require long hospital stays.

La cystite radio-induite (CR) est une complication tardive de la radiothérapie pelvienne se présentant notamment sous forme de troubles mictionnels irritatifs ou de macrohématurie récidivante. Le traitement est initialement conservateur ou endoscopique mais peut, dans des cas réfractaires, aboutir à une cystectomie à visée hémostatique ou fonctionnelle. L'oxygénothérapie hyperbare (OHB) a récemment fait son apparition dans les diagrammes de prise en charge de la CR réfractaire. Grâce à ses propriétés néoangiogéniques et à la stimulation des cellules souches, elle permet une résolution complète de l'hématurie chez près de deux tiers des patients et semble être une alternative thérapeutique pour cette population fragile. Actuellement, sa disponibilité géographique reste toutefois limitée en Suisse et sa réalisation implique parfois de longues hospitalisations.

Cistitis , Oxigenoterapia Hiperbárica , Humanos , Hematuria , Cistitis/etiología , Cistitis/terapia , Cistectomía , Geografía
World J Urol ; 40(12): 3001-3006, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36239808


PURPOSE: Robot-assisted simple prostatectomy (RASP) for benign prostatic hyperplasia (BPH) is a recently described surgical approach, but comparison with open simple prostatectomy (OSP) lack in the literature. We compared perioperative outcomes of OSP versus RASP. METHODS: Patients who underwent simple prostatectomy between 2017 and 2020 were included in this retrospective study. OSP was performed by the transvesical technique and RASP was performed with a DaVinci Xi robot, using the transvesical extraperitoneal approach. Perioperative and postoperative data were compared and complications risk factors for complications were identified. RESULTS: and limitations. Overall, 103 patients were included (median age 72 years [IQR = 67-76]). Forty-seven underwent RASP and 56 OSP. The median volume of the prostate gland was 130 mL [IQR = 100-180] in the RASP group and 126 mL [IQR = 100-160] in the OSP group. RASP was associated with a significant reduction in blood loss (median 200 vs. 400 mL; p < 0.001), shorter hospital stay (5 vs. 10 days; p < 0.001) and median catheterisation time (4 vs. 9 days; p < 0.001). In the RASP group, there were fewer grade ≥ 2 complications (2 (4.3%) vs. 13 (23.2%); p = 0.005) and less need for transfusions (0 vs. 6 (11%), p = 0.005). Preoperative prostate volume was a risk factor for complications (OR = 1.2 [95% CI 1.1-1.5]; p = 0.01) while robot-assisted surgery was a protective factor (OR 0.3 [95% CI 0.05-0.9]; p = 0.05). Functional outcomes between the two groups were identical at 12 months follow up. CONCLUSION: RASP is a safe and effective procedure. When compared with OSP, RASP was associated with decreased morbidity as well as reduced hospital stay and catheterisation time. Functional outcomes were comparable to the open approach.

Hiperplasia Prostática , Procedimientos Quirúrgicos Robotizados , Robótica , Masculino , Humanos , Anciano , Hiperplasia Prostática/complicaciones , Robótica/métodos , Procedimientos Quirúrgicos Robotizados/métodos , Estudios Retrospectivos , Resultado del Tratamiento , Prostatectomía/métodos
Int J Med Robot ; 18(6): e2462, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36121334


BACKGROUND: We lack data regarding the economic cost of robot-assisted surgical procedures in urology. We aimed to assess the medico-economic impact of onco-urological robot-assisted surgery. METHODS: All patients who underwent robot-assisted radical prostatectomy (RARP) or robot-assisted partial nephrectomy (RAPN) in 2019 were included. Cost assessment included the costs of surgery, hospital stay, and complications. Global cost was calculated and compared with open and laparoscopic procedures. RESULTS: Overall, 126 (48%) RAPN and 135 (52%) RARP were included. Total cost per patient was 6857€ for RARP and 6034€ for RAPN. Costs of surgery, hospital stay, and complications represented 76.2%, 21.5%, and 2.3%, respectively, of the total cost per patient for RAPN, and 74.1%, 25.9%, and 0% for RARP. Compared to the open approach, RAPN was 6% cheaper and RARP was 10% more expensive per patient. Standard laparoscopic procedures were cheaper. CONCLUSIONS: Robotic procedures were associated with increased costs of surgical procedures, but with reduction in morbidity and hospital stay costs.

Laparoscopía , Procedimientos Quirúrgicos Robotizados , Robótica , Masculino , Humanos , Procedimientos Quirúrgicos Robotizados/métodos , Prostatectomía/métodos , Nefrectomía/métodos , Laparoscopía/métodos
World J Urol ; 40(10): 2535-2541, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35994092


PURPOSE: Few data exist regarding the functional outcomes of robot-assisted radical cystectomy (RARC) with intracorporeal orthotopic neobladder. The aim of this study was to evaluate the urodynamic and functional outcomes in patients undergoing RARC and totally intracorporeal orthotopic neobladder for bladder cancer. METHODS: In this monocentric, observational study carried out between 2016 and 2020, consecutive patients undergoing RARC and intracorporeal orthotopic neobladder in the Department of Urology, Pitié-Salpêtrière Hospital, were included. Reconstruction was totally intracorporeal Y-shaped neobladder. Main outcomes were urodynamic findings 6 months post-surgery, continence and quality of life (QoL). Continence was defined by no pad or one safety pad. International Consultation on Incontinence Questionnaire (ICIQ), International Index of Erectile Function questionnaire (IIEF-5) and Bladder Cancer Index (BCI) scores were recorded. RESULTS: Fourteen male patients were included (median age: 64 years [IQR 54-67]. Median maximal neobladder cystometric capacity was 495 ml [IQR 410-606] and median compliance was 35.5 ml/cm H2O [IQR 28-62]. All patients had post-void residual volume < 30 ml, except for three (22%) who required clean intermittent-self catheterisation. Daytime continence was achieved in 10 patients (71%) and night-time continence in two (14.3%). Median ICIQ score was 7 [IQR 5-11]. Postoperative erectile function was present in 7% of patients (mean IIEF-5 = 5 [IQR 2-7]). Thirteen patients (93%) were satisfied with their choice of neobladder. CONCLUSION: RARC with totally intracorporeal orthotopic neobladder for bladder cancer provides satisfactory urodynamic results and good QoL. These findings should be confirmed long-term.

Disfunción Eréctil , Procedimientos Quirúrgicos Robotizados , Robótica , Neoplasias de la Vejiga Urinaria , Derivación Urinaria , Incontinencia Urinaria , Cistectomía/métodos , Disfunción Eréctil/etiología , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Procedimientos Quirúrgicos Robotizados/métodos , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/etiología , Neoplasias de la Vejiga Urinaria/cirugía , Derivación Urinaria/métodos , Incontinencia Urinaria/epidemiología , Incontinencia Urinaria/etiología , Incontinencia Urinaria/cirugía , Urodinámica
Urology ; 164: 145-150, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-35398464


OBJECTIVE: To assess the feasibility and safety of same-day discharge (SDD) surgery after robot-assisted partial nephrectomy (RAPN) in patients with small renal tumors. METHODS: Observational, monocentric study conducted over a one-year period. INCLUSION CRITERIA: good performance status, Charlson score <5, cT1a renal mass and RENAL score <6. EXCLUSION CRITERIA: coagulopathy or contraindication to outpatient surgery. RAPN was performed as the first case of the day. Anesthesia protocols allowed quick recovery and rapid hospital discharge. Patients were called systematically 1-day post-surgery to enquire about any early complications. Perioperative outcomes and complications were recorded according to Intraoperative adverse incident classification by the European Association of Urology and Clavien classifications 30- and 90-days post-surgery. Follow-up consultations were carried out with assessment of patient satisfaction. Primary outcomes were SDD failure, 30- and 90-day complications and readmission rate. Descriptive data were reported without statistical comparative analysis. RESULTS: Twenty patients were included (median age: 63 years [interquartile range: 57-64]). All patients were discharged home after a median surveillance time of 350 min (interquartile range: 270-420). One grade 1 intraoperative complication was reported. Two procedures were followed by an unplanned readmission due to early complications within the first 30 days (1 pain and anxiety [Clavien I], one active bleeding requiring embolization [Clavien IIIa]). The majority (85%) of patients were satisfied and would recommend day surgery. SDD failure rate was 10% at 90 days. CONCLUSION: RAPN is safe as a SDD procedure without major perioperative morbidity for selected tumors and patients.

Neoplasias Renales , Procedimientos Quirúrgicos Robotizados , Robótica , Humanos , Neoplasias Renales/patología , Persona de Mediana Edad , Nefrectomía/efectos adversos , Nefrectomía/métodos , Estudios Observacionales como Asunto , Alta del Paciente , Complicaciones Posoperatorias/etiología , Estudios Retrospectivos , Procedimientos Quirúrgicos Robotizados/efectos adversos , Procedimientos Quirúrgicos Robotizados/métodos , Resultado del Tratamiento